If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Emgality ® (galcanezumab-gnlm) injection
100 mg/mL, 120 mg/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
EMGALITY® (galcanezumab-gnlm): Half-Life
The elimination half-life of Emgality (galcanezumab) is 27 days.
Galcanezumab is an IgG4 monoclonal antibody and is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgG.1,2
The apparent clearance (CL/F) of galcanezumab-gnlm was 0.008 L/h and the elimination half-life of galcanezumab was approximately 27 days.1,2
Enclosed Prescribing Information
EMGALITY® (galcanezumab-gnlm) injection, for subcutaneous use, Lilly
The published reference below is available by contacting 1-800-LillyRx (1-800-545-5979).
1. Emgality [package insert]. Indianapolis, IN: Eli Lilly and Company; 2019.
2. Kielbasa W, Helton DL. A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody. Cephalalgia. 2019;39(10):1284-1297. http://dx.doi.org/10.1177/0333102419840780
CL/F = apparent clearance
IgG4 = immunoglobulin G (subclass) 4
IgG = immunoglobulin G
PK = pharmacokinetics
Date of Last Review: July 29, 2020